August 21, 2019
According to a company press release, Teva Pharmaceuticals announced it will now have a generic version of the FDA-approved EpiPen Jr (epinephrine injection, USP) Auto-Injector, 0.15 mg, available in most retail pharmacies. Teva said that the cost of the generic treatment will be $300 for a 2-pack.
”We’re pleased to provide access to Epinephrine Injection (Auto-Injector) in two strengths for patients who may experience life-threatening allergic emergencies,” said Brendan O’Grady, EVP and head of North America Commercial.
The generic treatment from Teva utilizes the Antares Pharma VIBEX device. Together, Teva and Antares have an exclusive License, Development and Supply Agreement for epinephrine auto injector products that Teva markets in the U.S.
“We will continue working to ensure availability of both strengths in the US and plan to accelerate production to meet the urgent need for this medicine,” noted Mr O’Grady.
Similar to Teva’s treatment, Mylan also has a generic version of the EpiPen allergy treatment. This is also priced at about $300.
EpiPens have been in shortage in the United States, Europe, and Canada due to a series of manufacturing delays at Pfizer Inc's Meridian Medical unit that produces all EpiPens sold globally
Teva Pharmaceuticals. Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States [press release]. https://ir.tevapharm.com/investors/press-releases/press-release-details/2019/Teva-Announces-Availability-of-a-Generic-Equivalent-of-EpiPen-Jr-epinephrine-injection-USP-Auto-Injector-015-mg-in-the-United-States/default.aspx. Published August 20, 2019. Accessed August 21, 2019.